We do. We have been collecting patient outcome data for quite some time and we regularly and openly publish the results with the public. To view this data, visit our Outcomes Page.
This is on a case-by-case basis and although we have before, it would be at the advice of the doctor to treat more than one area. One of the many things that set Regenexx procedures apart from all other stem cell therapy being offered is dosage; to ensure the best possible outcome the doctor takes many factors into consideration, including your stem cell count.
When we first began offering orthopedic stem cell therapy in 2005 as part of an IRB approved medical study, we were one of the few clinics in the world treating orthopedic problems with stem cells. When we began treating everyday patients in 2007, this was still the case. Now other clinics are beginning to offer basic cell therapies, most in plastic surgery and cosmetics, with a few clinics just starting to try orthopedic therapies. While we welcome the growth in cell based medicine, we also know that we’re world leaders in this area. As leaders, we set a higher standard for ourselves in all of the cell-based procedures we offer our patients.
We have 2 pages dedicated to explaining the substantial differences between Regenexx and other stem cell solutions:
No. PRP is concentrating platelets in the blood, not stem cell therapy. This is a more detailed discussion on the differences between PRP and stem cell therapy. In addition, while PRP is one component of the therapy, we use a very different “Super Platelet Mix’ which we believe helps to produce many more stem cells.
We do offer the Regenexx® Super Concentrated Platelet Rich Plasma Procedure, which is a platelet procedure that is quite different from the bloody PRP commonly available using bedside centrifuges. To see a patient infographic on these differences, see this link for general info on the Regenexx platelet procedure and this one for a comparison between our process and typical bedside PRP machines.
Our registry based research has shown that, for stem cell procedures, older age does not adversely impact outcome.
The same day procedure involves taking cells and then isolating those over one day.
The cultured procedure grows those cells to larger numbers over a period of a few weeks.
Call us to schedule a phone review of your images with one of our doctors or schedule an appointment with one of our approximately 30 Regenexx Network sites around the country.
We carefully hand pick only the doctors who have the base skills to perform these procedures, which means we turn most away. We then train our physicians with an intensive education program.
That depends on which procedure is performed.
For example, for knee arthritis, you can expect 3 days of significant down-time followed by a slow return to normal activities over 6 weeks. While you may be asked to wear a brace, very few of our procedures require crutches.
Many mechanisms have been put forth, including long-term blocking of cells that destroy the joint, rescue of cells that fix the joint, and replacing lost native stem cells that maintain the joint.
No, while we have seen MRI evidence of cartilage growth in mild and moderate arthritis, we generally don’t see it with severe arthritis.
Because the procedure protocol will vary from person to person and because each person will have a unique condition to be treated, the pricing of procedures can vary considerably from patient to patient. An evaluation will give you a better idea of condition, treatment and costs specific to your condition. The chart below provides a general idea of the procedures and where they fall in terms of cost and severity of conditions treated. Platelet procedures cost considerably less than stem cell procedures.
Typical Condition Severity
|$$$||Cultured Stem Cell Procedure (Cayman Islands Only)*|
|$$||Stem Cell Treatment Protocol (USA & Worldwide)|
|$||Platelet Rich Plasma & Platelet Lysate|
No, these procedures are too new to be covered yet. Don’t let someone fool you, PRP and stem cell injections have no insurance coverage at this time.
Some health insurance plans may cover the initial evaluation. If your plan does, and we are part of your insurance carrier network, we will bill the carrier. If not, there will be a consultation fee for the initial face to face consult.
We recommend that you contact your insurance carrier for more information about your specific coverage details.
While we prefer to see someone in person to review their condition and evaluate whether they would be a good candidate for Regenexx, many of our network doctors offer an initial phone review of your condition if it’s inconvenient for you to drive to your nearest provider for an office visit.
The doctor can look at your films, history, and speak to you on the phone about whether he or she believes this may help your problem. It’s important to note that this is not the formation of a traditional doctor–patient relationship until you actually visit the doctor. Rather, this is just an opportunity for the doctor to determine if you’re a reasonable candidate for the procedure and for you to ask addition questions.
The doctor will require an MRI on CD / DVD or an uploaded version of your MRI in order to review your imaging. Check with your local Regenexx provider on how to deliver your MRI to them.
There is a charge for phone reviews with a Regenexx doctor, so check with your local Regenexx Provider to learn more. If you are determined to be a qualified candidate and choose to have a procedure, this fee will be applied to the cost of a stem cell treatment. The fee is not applied to the cost of treatment for our platelet procedures, which are lower cost.
If your clotting times are normalized by taking clotting factors, then there should be no problem performing the procedure.
If you are under 110 pounds in weight, the doctor will likely decide to take less marrow or blood.
If your hematocrit is below 30 or your hemoglobin is below 10, we may not be able to perform the procedure. If your hematocrit is between 30-36 or hemoglobin below 12, we may try to limit the IV blood or marrow draw amounts and will have you follow-up with your family doctor.
We originally conducted clinical trials from 2005 – 2007, which were the first orthopedic stem cell procedures performed. Since that time, Regenexx has performed more of these procedures than any other clinic or medical group. The same-day procedure that is currently performed in the United States was developed in 2010 and has been continually improved since that time.
Because an x-ray will only show the condition of the bone, not the soft tissue, the doctor needs an MRI to accurately evaluate the condition of the whole area. If a patient is unable to have an MRI, a CT arthrogram is acceptable. We will review an x-ray for non-union fractures only.
The doctor will need the most recent MRI available. The MRI should be without contrast and less than two years old. If you’ve had surgery or a scope done since having the MRI, we would need an MRI that was taken after the operation / procedure.
No, they are simply your own adult stem cells. We only use autologous (your own) cells.
Cord stem cells are stem cells isolated from a baby’s umbilical cord. While they may be more biologically active because of their young age, recent research has suggested that they can also transmit genetic diseases that the baby may carry. Until these issues are further sorted out (likely with better genetic testing), we would advise against using any donor stem cells to treat non-life threatening disease. (cells from another person). This would include cord cells, embryonic stem cells, or someone else’s adult stem cells.
Yes, there are many types of adult stem cells. The most common is known as a hematopoetic stem cells (HSC-CD 34+). These are easy to obtain from IV mobilized blood (where a special medicine is given to the patient first to push these cells out of the bone marrow) or bone marrow and are very plentiful. Outside of a handful of cardiac and vascular applications, they are not well studied as being effective in treating a broad range of diseases. Despite this, the vast majority of what you see being billed as “stem cells” from bone marrow (where the cells are injected the same day as collected) are these less useful cells. The type of adult stem cell that is most often seen in research as being associated with orthopedic tissue repair is a mesenchymal stem cell (MSC). MSCs can’t generally be harvested from blood. Fat tissue contains many MSCs, but these are distant cousins to the type obtained from bone marrow and aren’t as useful for orthopedic applications. For more more information on why stem cells from fat aren’t as useful as those from marrow to treat orthopedic injuries, click here. For an easy to understand patient infographic on why bone marrow stem cells are better than fat cells for orthopedic tissue repair, click here.
For orthopedic applications, two main types of MSCs have been used, bone marrow derived and adipose (fat) derived. Bone marrow MSCs are taken via a needle through a bone marrow aspirate. The bone marrow aspiration procedure sounds like a big deal, but we are consistently told by patients that the procedure is very comfortable. The second type of MSC is derived from fat tissue (adipose). This can be obtained via liposuction. For orthopedic applications, fat derived MSCs consistently and dramatically under perform bone marrow derived cells. In studies of cartilage repair, bone repair, and soft-tissue repair, bone marrow derived MSCs are much more adept at these tasks. This makes sense, as they perform this function naturally (homologous) everyday. For example, if you break a bone, it’s these bone marrow MSCs that help mend that bone. In addition, for surgical micro fracture to repair small amounts of knee cartilage damage, it’s bone marrow MSC’s that are released to do that job.
Yes and No. First, many adipose stem cell clinics dramatically over-estimate the number of stem cells in their processed fat. This is a good hard core science review of the kits often used by physicians which over estimate these numbers. Basically, what physicians believe to be cells are actually small globs of fat tissue. Second, the proprietary Regenexx stem cell isolation method dramatically increases the number of stem cells isolated from bone marrow (based on our lab studies).
Still, on a weight to weight basis, fat can contain more mesenchymal stem cells than bone marrow, but the problem is that they just don’t work as well for orthopedic applications (click here for more information on this topic). In addition, in the Regenexx-AD knee stem cell procedure we offer the best of both worlds, bone marrow and fat.
MSC’s do stay localized to the injection site across multiple studies. This is likely linked to the fact that they generally do not circulate in the blood stream like other adult stem cell types and are primarily found resident in the tissues they serve.
Mesenchymal stem cells will stop proliferating when they physically contact each other (otherwise known in cell culture lingo as “confluence”). Culturing these cells, it becomes obvious that once they reach that point, they refuse to continue to grow (proliferate). This is because they are repair cells and when an area in need of repair is fully covered, they get the signal to stop growing. In patients where we have ongoing MRI surveillance of the re-implant sites, there has been no evidence of overgrowth where the regeneration has surpassed “expected optimal growth”.
Unlike embryonic stem cells, adult stem cells do not generally keep growing, even in culture. For example, most patients whose stem cells we grow to bigger numbers in the lab will lose their ability for continued cell growth after just a few weeks. In addition, the same body signals that would tell these cells to stop growing in healing a normal fracture or ligament tear are still present in your body.
No, an analysis of the published research shows that liposuction is more risky than a bone marrow aspirate. More information on this can be found at the link below:
Approximately 10 years.
Using the HHS OHRP guidelines for complications reporting, our complications to date have been in the mild to moderate category and rare. This means that either the complication (like transient swelling) required no medical treatment (Mild), or if it did require medical treatment, the treatment was simple (Moderate-like a patient who failed the procedure who ultimately decided to get the knee replacement that he or she was planning before the procedure). We have published the world’s largest (to date) safety and complications tracking study of adult stem cell use in patients. This study did not show any serious stem cell related complications and it did not show that any patient developed a stem cell related cancer. In addition, our most recent safety paper was named the best of it’s type by a meta-analysis that appeared in the prestigious medical journal, Osteoarthritis and Cartilage.
The basic science on adult stem cells shows that if the cells are kept in culture for short periods, there is no risk of the cells becoming cancerous. We have published the world’s largest (to date) safety and complications tracking study of adult stem cell use in patients. This study did not show any serious stem cell related complications and it did not show that any patient developed a stem cell related cancer. Finally, we maintain an extensive complications tracking database with patient contacts at specified times. We have seen no evidence of significant complications at these re-implant sites. We also work with an outside lab for quality to clear each patient’s cells before they are used in treatment as an additional safety check.
The FDA does not “approve” or “not approve” medical procedures (like gall bladder surgery for example). This is considered a medical procedure.
All of the Regenexx Stem Cell and Blood Platelet Procedures performed in the U.S. today are same-day procedures that are compliant with CFR 21 Part 1271, falling under the same surgery exemption discussed in 1271.15 (b).
The Regenexx-C Procedure – What’s the Difference?
All of the procedures performed throughout our U.S. Regenexx Procedure Network are same-day procedures. This means that the patient’s cells are harvested in the morning, isolated and processed, then re-injected into the patient’s injured area – all within a period of a few hours. This makes them compliant with CFR 21 Part 1271, falling under the same surgery exemption discussed in 1271.15 (b).
Regenexx®-C is a cultured stem cell procedure that is available only in the Cayman Islands. While our same-day stem cell protocol (described above) is the premier stem cell treatment available in the United States, some patients may benefit from the expanded numbers of cells that are delivered by a cultured stem cell procedure.
The Regenexx-C Procedure, which is only performed at Regenexx Cayman, involves harvesting the cells on the patient’s first visit, growing them to larger numbers over approximately two weeks, testing the cells, then re-injecting the cells during the patient’s second visit.